Nasrien Ibrahim, M.D.

Associate Director, Resynchronization and Advanced Cardiac Therapeutics Program
Massachusetts General Hospital 

Blog | Nasrien Ibrahim, M.D. Heart Failure|

Key Heart Failure Takeaways at AHA 2019

John J. V. McMurray presenting the DAPA-HF Trial at AHA 2019. It was part of the late-breaking presentations in the "Outside the Box: New Approaches to CVD Risk Reduction" session.

John J. V. McMurray presenting the DAPA-HF Trial at AHA 2019. It was part of the late-breaking presentations in the "Outside the Box: New Approaches to CVD Risk Reduction" session. Photo by AHA/Phil McCarten


It’s an exciting time in the heart failure (HF) world right now with the emergence of new therapies, including medications and devices. Several of these were highlighted in sessions at the 2019 American Heart Association (AHA) scientific sessions.

Late-breaking Clinical Trials in Heart Failure at AHA 2019

Several sub-studies of landmark HF trials were presented as late-breaking presentations. These included:
   • The Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction (DAPA-HF) trial [1];
   • The Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction (PARAGON-HF) trial; and 
   • The Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure (PARADIGM-HF) trial. 

DAPA-HF investigators presented data that showed dapagliflozin improved symptoms and reduced the risk of cardiovascular death and worsening heart failure events across all age groups of patients with HF with reduced ejection fraction (HFrEF).  Read more about this trial

PARAGON-HF investigators presented data showing that compared to valsartan, sacubitril/valsartan reduced the risk of HF hospitalization more in women than in men. Investigators from PARAGON-HF and PARADIGM-HF presented exciting data for patients with mild or mid-range ejection fraction (HFmEF) HF showing that the therapeutic effects of sacubitril/valsartan extend to patients with HFmEF and benefits appeared to extend to a higher ejection fraction range in women compared with men. Read more about this trial

 

Ambulatory Pulmonary Artery Pressure Monitoring Device Shows Promise

 SIRONA first-in-human study, which described a pro-active heart failure management strategy incorporating ambulatory pulmonary artery pressure monitoring with the Cordella Heart Failure System.Also exciting was the presentation of the SIRONA first-in-human study, which described a pro-active heart failure management strategy incorporating ambulatory pulmonary artery pressure monitoring with the Cordella Heart Failure System. The 90-day data confirmed device safety and accuracy of pressure measurements in the right pulmonary artery and high patient adherence rate due to ease of pressure monitoring. The technology uses an implantable PA monitor and a handheld patient reader.

Read more about this technolology and the data presented at AHA.

 

 

New Drug Vericiguat May Impact Heart Failure Care

There was an announcement by drug makers Merck and Bayer the week of AHA 2019 that its vericiguat agent in development met the primary endpoint in the VICTORIA phase 3 study of patients with worsening chronic HFrEF. The endpoint was to lower heart failure hospitalization and cardiac death compared to placebo. The details of that study are slated for presentation at a medical conference in 2020.

 

Remote Titration of Optimal Medical Therapy in Heart Failure 

Akshay Desai, M.D., medical director, Cardiomyopathy and Heart Failure Program, advanced heart disease section, presented data at AHA on a navigator-led, remote guideline-directed medical therapies (GDMT) optimization program for patients with HFrEF. The study showed promising results and improved GDMT uptake. 

Akshay Desai presentation AHA 2019 data at AHA on a navigator-led, remote guideline-directed medical therapies (GDMT) optimization program for patients with HFrEF.Optimal treatment of HFrEF is scripted by treatment guidelines, but many patients do not receive GDMT in clinical practice. Investigators developed an algorithm-driven, navigator-administered medication optimization program that would enhance implementation of GDMT compared with usual care in patients. Patients were contacted via phone by a navigator who facilitated medication adjustment with surveillance of laboratories, blood pressure, and symptoms under supervision of a pharmacist, nurse practitioner, and HF cardiologist.

The results were patients in the remote intervention experienced greater increases from baseline in utilization of all categories of GDMT than those in the usual care group. The proportion of patients advanced to target doses of GDMT was also higher in the intervention group at three months. Desai said remote titration of GDMT by navigators using encoded algorithms may represent an efficient, population-level strategy for rapidly closing the gap between guidelines and clinical practice.

Programs like this and use of remote device monitoring should be incorporated to reduce the burden of frequent patient appointments and assist clinicians in optimizing therapies for patients with HF.

 

Find links to all the AHA late-breaking trials and other key news.

References:

1. Felipe A. Martinez, Matteo Serenelli, Jose C. Nicolau, et al. Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age: Insights From DAPA-HF. Circulation. Originally published online 17 Nov 2019. https://ahajournals.org/doi/10.1161/CIRCULATIONAHA.119.044133.

2. John J. V. McMurray, Alice M. Jackson, Carolyn S.P. Lam, et al. Effects of Sacubitril-Valsartan, versus Valsartan, in Women Compared to Men with Heart Failure and Preserved Ejection Fraction: Insights from PARAGON-HF. Circulation. Originally published online 17 Nov 2019. https://ahajournals.org/doi/10.1161/CIRCULATIONAHA.119.044491.

3. Scott D. Solomon, Muthiah Vaduganathan, Brian L. Claggett, et al. Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure.  Circulation. Originally published online 17 Nov 2019. https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.119.044586.

 

 

Related Content

News | AHA

September 20, 2021 — The American Heart Association (AHA) announced Sept. 16 it decided to convert from a planned in ...

Home September 20, 2021
Home
Feature | AHA | Dave Fornell, Editor

Here is a list of the American Heart Association (AHA) late-breaking clinical trial presentations at the 2020 Virtual ...

Home November 20, 2020
Home
News | AHA

July 15, 2020 – The last major cardiovascular conference to go virtual in 2020 due to the COVID-19 (SARS-Cov-2) pandemic ...

Home July 15, 2020
Home
News | AHA

November 22, 2019 — Artificial intelligence can examine electrocardiogram (ECG) test results, a common medical test, to ...

Home November 22, 2019
Home
News | AHA

November 21, 2019 — At the American Heart Association Scientific Sessions 2019, Eko, a digital health company applying ...

Home November 21, 2019
Home
News | AHA

November 21, 2019 — People who experience cardiac arrests over the weekend are less likely to survive long enough to be ...

Home November 21, 2019
Home
News | AHA

November 20, 2019 — Heart attack survivors may have an increased risk of developing cancer compared to people without ...

Home November 20, 2019
Home
News | AHA

November 20, 2019 — Ultra-processed foods, which account for more than half of an average American’s daily calories, are ...

Home November 20, 2019
Home
News | AHA

November 20, 2019 — Frequent cannabis (marijuana) use among young people was linked to an increased risk of stroke, and ...

Home November 20, 2019
Home
Feature | AHA

November 19, 2019 — After 12 years of collecting data, the results of the landmark ISCHEMIA (International Study of ...

Home November 19, 2019
Home
Subscribe Now